Leadership Team

David Kennard

Gilead and CRUK Track Record

Corporate & Business Development Veteran

Biotech leader with PhD and MBA

Treehill Partners

Focused on Transactions and Transitions in Healthcare

Diverse senior team with complementary backgrounds from banking & finance, strategic consulting, and leadership roles in industry. In-house medical, scientific, product development and commercialization expertise

Dr David Kennard is leading Industry Relations at Treehill Partners. He is a seasoned biopharma veteran with successful track records across corporate leadership, business development, as well as product and technology transactions.

At Treehill, David is focused on creating and maintaining dialogues with industry players large and small, associations, institutions, and service providers. He supports selected assignments with a huge depth of biotech specific insight and expertise. He puts to work a synthesis of strategic, commercial and interpersonal skills, drug development know-how, and scientific understanding when supporting clients thinking outside the box. David has worked for three decades across all aspects of the healthcare industry. His proactive, commercial approach and ability to manage complexity has yielded success across leadership positions from large-cap pharma to start-ups.

At Treehill, David is focused on creating and maintaining dialogues with industry players large and small, associations, institutions, and service providers. He supports selected assignments with a huge depth of biotech specific insight and expertise. He puts to work a synthesis of strategic, commercial and interpersonal skills, drug development know-how, and scientific understanding when supporting clients thinking outside the box. David has worked for three decades across all aspects of the healthcare industry. His proactive, commercial approach and ability to manage complexity has yielded success across leadership positions from large-cap pharma to start-ups.

Prior to joining Treehill, David was a Senior Advisor to Corporate Development at Gilead, where he was involved in search and evaluation of product opportunities for Gilead’s core therapeutics areas. Before its acquisition by Gilead in Feb-13, David was at YM BioSciences (most recently Vice President Strategic Alliances), NeuroTargets (CEO), SR Pharma (COO), and GlaxoSmithKline.

He holds a PhD in Biochemistry and a Bachelor of Pharmacy from University College London, as well as an MBA from The Open University Business School.